Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2420 June 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
Fax Number:  Trastuzumab deruxtecan		Fax Number:
Initial application Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)  Patient is currently on treatment with trastuzumab deruxtecan and met all remaining criteria prior to commencing treatment  Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology)  Patient has previously received trastuzumab and chemotherapy, separately or in combination  and  The patient has received prior therapy for metastatic disease  or  The patient developed disease recurrence during, or within six months of completing adjuvant therapy  and  Patient has a good performance status (ECOG 0-1)  and  Patient has not received prior funded trastuzumab deruxtecan treatment  and  Treatment to be discontinued at disease progression		
Renewal  Current approval Number (if known):		
The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab deruxtecan  and  Treatment to be discontinued at disease progression		
Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.		